Jentadueto Receives European Commission Marketing Authorisation

European regulators have given approval to Boehringer Ingelheim and Eli Lilly’s diabetes combo drug, Jentadueto. The pharmaceutical organisations announced earlier today that they received marketing authorisation from the European Commission (EC) for Jentadueto, which combines metformin with the dipeptidyl peptidase (DPP)-IV inhibitor Trajenta (linagliptin) in a single pill. The approval was expected after the European

Continue Reading

Final NICE Approval for Eli Lilly’s Bydureon

The UK’s National Institute for Health and Clinical Excellence (NICE) announced yesterday that they had confirmed in final guidance a endorsement of the use of Eli Lilly’s Bydureon (prolonged-release exenatide) in triple-therapy regimens as a treatment option for people with type 2 diabetes. The director of NICE’s centre for health technology evaluation, Professor Carole Longson,

Continue Reading

NICE Draft OK for Eli Lilly Diabetes Drug

The UK’s National Institute for Health and Clinical Excellence (NICE) have issued an initial recommendation of approval for the use of Eli Lilly’s Bydureon (exenatide prolonged-release suspension for injection) in triple-therapy options for people with type 2 diabetes, when control of blood glucose remains or becomes inadequate. NICE commented that Bydureon improves glycaemic control in

Continue Reading

Diabetes is pharma’s fastest-growing market

Diabetes is the pharmaceutical industry’s fastest-growing market, and the costs of preventing and treating the condition worldwide are forecast to rise from $376 billion in 2010 to $490 billion by 2030, according to new research.  285 million people, or 6.4% of the world’s adult population, are currently estimated to be living with diabetes, and this

Continue Reading